Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.56 |
| ▸ | HTT | P42858 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20026965 | 0.91 | ALDH1A1 (0.60) | LMNAHTTALDH1A1GAAMAPT | |
| SCHEMBL19420682 | 0.90 | ALDH1A1 (0.58) | LMNAHTTALDH1A1GAAMAPT | |
| SCHEMBL9800938 | 0.86 | EPHX2 (0.51) | LMNAHTTALDH1A1GAAMAPT | |
| SCHEMBL9800937 | 0.86 | EPHX2 (0.51) | LMNAHTTALDH1A1GAAMAPT | |
| SCHEMBL23505645 | 0.84 | ALDH1A1 (0.53) | LMNAHTTALDH1A1GAAMAPT | |
| SCHEMBL11757878 | 0.83 | KMT2A (0.69) | LMNAHTTALDH1A1GAAMAPT | |
| SCHEMBL6097794 | 0.82 | POLB (0.60) | LMNAHTTALDH1A1GAAMAPT | |
| SCHEMBL22454914 | 0.81 | ALDH1A1 (0.54) | LMNAHTTALDH1A1GAAMAPT | |
| SCHEMBL19420698 | 0.81 | ALDH1A1 (0.51) | LMNAHTTALDH1A1GAAMAPT | |
| SCHEMBL11133485 | 0.81 | LMNA (0.45) | LMNAHTTALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843949-B | Thioguanidine group IV transition metal catalysts and polymerization systems | 陶氏环球技术有限责任公司 | 2021-08-10 | — | — | CN | disclosed |
| EP-3519463-B1 | THIOGUANIDINE GROUP IV TRANSITION METAL CATALYSTS AND POLYMERIZATION SYSTEMS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10647799-B2 | Thioguanidine group IV transition metal catalysts and polymerization systems | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647799-B2 | Thioguanidine group IV transition metal catalysts and polymerization systems | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190263949-A1 | THIOGUANIDINE GROUP IV TRANSITION METAL CATALYSTS AND POLYMERIZATION SYSTEMS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263949-A1 | THIOGUANIDINE GROUP IV TRANSITION METAL CATALYSTS AND POLYMERIZATION SYSTEMS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647799-B2 | Thioguanidine group IV transition metal catalysts and polymerization systems | HBG2, QSOX1, HBG1 | LMNA 4615/4885HTT 717/4885ALDH1A1 1200/4885 |
| US-20190263949-A1 | THIOGUANIDINE GROUP IV TRANSITION METAL CATALYSTS AND POLYMERIZATION SYSTEMS | HBG2, QSOX1, HBG1 | LMNA 4615/4885HTT 717/4885ALDH1A1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.